Clinical Trial

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-17; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT06944145
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Enrollment 242 participants
Start Date 2025-12-03
Primary Completion 2029-06-01 (estimated)
Study Completion 2030-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-23